The treatment landscape for C3G has historically depended on the off-label use of multiple prescription therapies, underscoring the ...

Please be advised that this call is being recorded at the company's request, and a replay will be available on the company's website. I'll now turn the call over to Jennifer Williams, Investor ...

C3 glomerulopathy (C3G) and immune complex membranoproliferative glomerulonephritis (IC-MPGN) are rare kidney conditions caused by an overactive complement system, part of the immune system. C3G ...

A rare but severe stem cell transplant complication that often becomes fatal now has its first FDA-approved treatment, a therapy developed by biotechnology company Omeros. The Christmas Eve regulatory ...

(RTTNews) - Omeros Corp. (OMER) said Thursday that the U.S. Food and Drug Administration has approved Yartemlea (narsoplimab-wuug) for the treatment of hematopoietic stem cell transplant-associated ...

Novo Nordisk is paying $240 million for global rights to a Phase 3-ready drug from Omeros that could rival immune disorder medications currently available from companies such as AstraZeneca, Novartis, ...

The complement lectin pathway is thought to be a key player in renal ischemia–reperfusion injury (IRI), a frequent issue after kidney transplantation. IRI can result in graft failure and increased ...

SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) today reported that clinical trial site activation for enrollment is underway for the company’s Phase 3 program evaluating zaltenibart in ...

Share on Pinterest A study offers new clues on why long COVID persists in some individuals. krisanapong detraphiphat/Getty Images Despite the debilitating nature of long COVID, there is an absence of ...

Just a few months after discontinuing its most advanced pipeline asset, BioCryst Pharmaceuticals is now delaying testing of its only remaining clinical candidate. The oral factor D inhibitor, dubbed ...